AstraZeneca (NASDAQ:AZN) used its presentation at the J.P. Morgan Healthcare Conference to highlight strong 2025 performance, ...
AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use ...
Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.
AstraZeneca (AZN) is one of the fast-growing pharmaceutical companies that has played a significant role in saving the lives of COVID-19 patients and is known worldwide for innovative medicines such ...
CAMBRIDGE, England--(BUSINESS WIRE)--Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through ...
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company. Already ...
Its weight loss drug candidate has generated some buzz after a successful clinical trial. While the data is encouraging, the competitive landscape in weight loss is intense. AstraZeneca trades at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback